Inhibikase Therapeutics Inc (IKT) Stock Price, Quote & News

Company Profile

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to im...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 295 3800

Website: www.inhibikase.com

Address:

1000 N. West Street, Suite 1200, Wilmington, United States

OfficialStocktwitsUser May. 8 at 1:45 AM

$IKT RSI: 61.43, MACD: 0.0519 Vol: 0.10, MA20: 1.84, MA50: 1.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing May. 5 at 2:09 PM

$IKT Current Stock Price: $1.98

0 · Reply

garygb Apr. 18 at 11:35 PM

$IKT Running after hours.

1 · Reply

TJC1791 Apr. 11 at 10:02 PM

$IKT https://chatgpt.com/share/69dac4b8-8fc4-8322-b333-ddf8b58519e8

0 · Reply

StockMarketInvestments Apr. 9 at 12:41 PM

$IKT Maybe Milton Werner's ABLi Therapeutics Company can bail out IKT down the road, maybe.

2 · Reply

StockMarketInvestments Apr. 9 at 12:23 PM

$IKT This is basically a dead stock until March, April or May of 2027. Another year of bag holding and missed opportunities, with no guaranties that when that time and readout gets here that the wait will be worth it in the stock price. IKT doesn't seem to think there stock is attractive enough for them to buy huge amounts of their companies shares in the open market, could then be considered a lack of confidence and that they just want to ride their current gravy train.......

1 · Reply

StockMarketInvestments Apr. 8 at 2:08 PM

$IKT This has long since turned out to be another one of this person's money losing shit stocks recommended by a supposedly financially, biotech and BP knowledgeable person.

0 · Reply

focafoca99 Apr. 7 at 9:32 PM

$IKT enrolled the first patient in its pivotal Phase 3 IMPROVE-PAH study of IKT-001.

0 · Reply

TJC1791 Apr. 7 at 8:59 PM

$IKT

0 · Reply

freshcoast22 Apr. 7 at 6:52 PM

$IKT No safety data til 2027. No upcoming catalysts. These analysts, at the banks that have deals with IKT, keep pumping this shit so they can unload more of the shelf without crushing the price. Gross

0 · Reply

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

2026-04-07T12:42:54.000Z - 5 weeks ago

Inhibikase Therapeutics enrolls first patient in IMPROVE-PAH study

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Apr 3, 2026, 2:01 PM EDT - 5 weeks ago

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 26, 2026, 4:01 PM EDT - 6 weeks ago

Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity

2026-03-04T12:41:55.000Z - 2 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-03-04T11:48:05.000Z - 2 months ago

Inhibikase Therapeutics initiated with a Buy at Ladenburg

2026-01-21T11:31:15.000Z - 4 months ago

Inhibikase Therapeutics initiated with a Buy at BofA

2025-12-11T13:00:48.000Z - 5 months ago

Inhibikase Therapeutics initiated with an Overweight at Cantor Fitzgerald

2025-11-21T04:00:11.000Z - 6 months ago

Inhibikase Therapeutics 46.1M share Spot Secondary priced at $1.45

Nov 20, 2025, 9:54 PM EST - 6 months ago

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:50:22.000Z - 6 months ago

Inhibikase Therapeutics TBA Spot Secondary; reoffered at $1.45

2025-11-20T21:15:17.000Z - 6 months ago

Inhibikase announces common stock and warrants offering, no amount given

Nov 20, 2025, 4:12 PM EST - 6 months ago

Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2025-11-20T21:11:51.000Z - 6 months ago

Inhibikase Therapeutics to advance IKT-001 to Phase 3 clinical study in PAH

Nov 20, 2025, 4:01 PM EST - 6 months ago

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Nov 14, 2025, 4:01 PM EST - 6 months ago

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

2025-08-19T12:15:43.000Z - 9 months ago

Inhibikase Therapeutics appoints Pigot as Chief Commercial, Strategy Officer

Aug 19, 2025, 8:00 AM EDT - 9 months ago

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Aug 14, 2025, 4:50 PM EDT - 9 months ago

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

2025-06-20T21:10:07.000Z - 11 months ago

Inhibikase Therapeutics files $300M mixed securities shelf

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity

2025-04-14T12:15:44.000Z - 1 year ago

Inhibikase Therapeutics announces appointment of McIntyre as CFO

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

2025-02-24T13:15:39.000Z - 1 year ago

Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO

Feb 24, 2025, 8:00 AM EST - 1 year ago

Inhibikase Announces Expansion of Senior Leadership Team

2025-02-18T13:26:26.000Z - 1 year ago

Inhibikase Therapeutics appoints Mark Iwicki as CEO

Feb 18, 2025, 8:00 AM EST - 1 year ago

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth

2025-02-12T11:10:56.000Z - 1 year ago

Inhibikase Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Jan 29, 2025, 6:30 PM EST - 1 year ago

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

2024-11-18T21:55:25.000Z - 1 year ago

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders

2024-11-14T13:46:36.000Z - 1 year ago

Inhibikase Therapeutics reports Q3 EPS (65c), consensus (48c)

Nov 14, 2024, 8:37 AM EST - 1 year ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

2024-11-08T00:05:16.000Z - 1 year ago

Inhibikase Therapeutics initiated with a Buy at Jefferies

Oct 21, 2024, 9:05 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Oct 17, 2024, 9:00 AM EDT - 1 year ago

Inhibikase Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 9, 2024, 9:18 AM EDT - 1 year ago

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:25 PM EDT - 1 year ago

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 17, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Jun 5, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

May 20, 2024, 8:01 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

May 16, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q1 2024

May 15, 2024, 8:00 PM EDT - 2 years ago

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

May 15, 2024, 8:45 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

May 9, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Apr 18, 2024, 4:30 PM EDT - 2 years ago

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

Apr 3, 2024, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q4 2023

Mar 27, 2024, 4:15 PM EDT - 2 years ago

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Mar 7, 2024, 8:30 AM EST - 2 years ago

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Feb 28, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Feb 7, 2024, 7:55 AM EST - 2 years ago

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

Jan 29, 2024, 9:05 AM EST - 2 years ago

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Jan 16, 2024, 4:05 PM EST - 2 years ago

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Dec 4, 2023, 8:35 AM EST - 2 years ago

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

Nov 15, 2023, 8:00 AM EST - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Nov 7, 2023, 9:28 AM EST - 2 years ago

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson's Disease and Provides Update on Ongoing Enrollment

Oct 4, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy

Aug 24, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders

Aug 21, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib

Aug 17, 2023, 8:30 AM EDT - 2 years ago

Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Inhibikase Therapeutics Earnings Call Transcript: Q2 2023

Aug 7, 2023, 8:05 AM EDT - 3 years ago

Inhibikase Therapeutics to Report Second Quarter Financial Results on August 14, 2023

Jul 17, 2023, 4:05 PM EDT - 3 years ago

Inhibikase Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jun 29, 2023, 9:29 AM EDT - 3 years ago

Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split

Jun 22, 2023, 8:05 AM EDT - 3 years ago

Inhibikase Therapeutics Announces Selection of the Bioequivalent Dose of IkT-001Pro and Provides Update on the '501' Bioequivalence Study

Jun 21, 2023, 8:05 AM EDT - 3 years ago

Inhibikase Therapeutics Initiates Medical and Patient Awareness Campaign for its Phase 2 '201' Trial Evaluating IkT-148009 in Parkinson's Disease

OfficialStocktwitsUser May. 8 at 1:45 AM

0 · Reply

BillionerOfKing May. 5 at 2:09 PM

$IKT Current Stock Price: $1.98

0 · Reply

garygb Apr. 18 at 11:35 PM

$IKT Running after hours.

1 · Reply

TJC1791 Apr. 11 at 10:02 PM

$IKT https://chatgpt.com/share/69dac4b8-8fc4-8322-b333-ddf8b58519e8

0 · Reply

StockMarketInvestments Apr. 9 at 12:41 PM

$IKT Maybe Milton Werner's ABLi Therapeutics Company can bail out IKT down the road, maybe.

2 · Reply

StockMarketInvestments Apr. 9 at 12:23 PM

1 · Reply

StockMarketInvestments Apr. 8 at 2:08 PM

$IKT This has long since turned out to be another one of this person's money losing shit stocks recommended by a supposedly financially, biotech and BP knowledgeable person.

0 · Reply

focafoca99 Apr. 7 at 9:32 PM

$IKT enrolled the first patient in its pivotal Phase 3 IMPROVE-PAH study of IKT-001.

0 · Reply

TJC1791 Apr. 7 at 8:59 PM

$IKT

0 · Reply

freshcoast22 Apr. 7 at 6:52 PM

0 · Reply

TJC1791 Apr. 2 at 6:54 AM

$IKT I wonder if they announce 1st patient now.

0 · Reply

TJC1791 Apr. 2 at 6:51 AM

$IKT https://d1io3yog0oux5.cloudfront.net/_cabc3379609ac05570ab01f627f0b13c/inhibikase/db/935/9129/pdf/IKT+Corp+Deck+April+2026+vF.pdf

0 · Reply

TJC1791 Mar. 26 at 8:32 PM

$IKT https://chatgpt.com/share/69c596f9-ffc4-8323-a0ff-0d0b55a783f7

0 · Reply

TJC1791 Mar. 26 at 8:21 PM

$IKT The Company is progressing regulatory approvals with submissions in over 20 countries together with receiving confirmation of acceptance under “Facilitating and Accelerating Strategic Trials in the European Union”, called FAST-EU, which is a pilot initiative that commenced on January 30, 2026 to accelerate the approval of multinational clinical trials. FAST-EU offers a potential maximum 10-week (70-day) timeline for authorization, integrating Ethics Committee opinions and improving efficiency within the European Union Clinical Trials Information System.

2 · Reply

TJC1791 Mar. 26 at 8:08 PM

$IKT https://www.inhibikase.com/news/press-releases/detail/138/inhibikase-therapeutics-announces-full-year-2025-financial

0 · Reply